Clementia Pharmaceuticals Inc., of Montreal, said it started a phase II trial of palovarotene, a retinoic acid receptor gamma agonist, for the treatment of fibrodysplasia ossificans progressive (FOP), a rare, genetic disease characterized by painful, recurrent episodes of soft tissue swelling and abnormal bone formation in muscles, tendons and ligaments.